Abstract
Since Warburg proposed in 1956 that cancer cells exhibit increased glycolysis due to mitochondrial damage, numerous researchers have assumed that glycolysis is the predominant ATP supplier for cancer cell energy-dependent processes. However, chemotherapeutic strategies using glycolytic inhibitors have been unsuccessful in arresting tumor proliferation indicating that the Warburg hypothesis may not be applicable to all existing neoplasias. This review analyzes recent information on mitochondrial metabolism in several malignant neoplasias emphasizing that, although tumor cells maintain a high glycolytic rate, the principal ATP production may derive from active oxidative phosphorylation. Thus, anti-mitochondrial drug therapy may be an adequate adjuvant strategy to arrest proliferation of oxidative phosphorylation-dependent neoplasias.
Keywords: Anti-mitochondrial drugs, glycolysis, oxidative phosphorylation, Warburg hypothesis, multi-site therapy, multi-drug therapy, respiratory inhibitors, uncouplers, lipophilic cation drugs, mitochondrial substrate oxidation, Krebs cycle
Current Medicinal Chemistry
Title: Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Volume: 18 Issue: 21
Author(s): Sara Rodriguez-Enriquez, Juan Carlos Gallardo-Perez, Alvaro Marin-Hernandez, Jose Luis Aguilar-Ponce, Edna Ayerim Mandujano-Tinoco, Abelardo Meneses and Rafael Moreno-Sanchez
Affiliation:
Keywords: Anti-mitochondrial drugs, glycolysis, oxidative phosphorylation, Warburg hypothesis, multi-site therapy, multi-drug therapy, respiratory inhibitors, uncouplers, lipophilic cation drugs, mitochondrial substrate oxidation, Krebs cycle
Abstract: Since Warburg proposed in 1956 that cancer cells exhibit increased glycolysis due to mitochondrial damage, numerous researchers have assumed that glycolysis is the predominant ATP supplier for cancer cell energy-dependent processes. However, chemotherapeutic strategies using glycolytic inhibitors have been unsuccessful in arresting tumor proliferation indicating that the Warburg hypothesis may not be applicable to all existing neoplasias. This review analyzes recent information on mitochondrial metabolism in several malignant neoplasias emphasizing that, although tumor cells maintain a high glycolytic rate, the principal ATP production may derive from active oxidative phosphorylation. Thus, anti-mitochondrial drug therapy may be an adequate adjuvant strategy to arrest proliferation of oxidative phosphorylation-dependent neoplasias.
Export Options
About this article
Cite this article as:
Rodriguez-Enriquez Sara, Carlos Gallardo-Perez Juan, Marin-Hernandez Alvaro, Luis Aguilar-Ponce Jose, Ayerim Mandujano-Tinoco Edna, Meneses Abelardo and Moreno-Sanchez Rafael, Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias, Current Medicinal Chemistry 2011; 18 (21) . https://dx.doi.org/10.2174/092986711796391561
DOI https://dx.doi.org/10.2174/092986711796391561 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets Stem Cell-Derived Microvesicles: A Cell Free Therapy Approach to the Regenerative Medicine
Current Biotechnology Preclinical Evaluation of New Anthracyclines
Current Medicinal Chemistry Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era
Anti-Cancer Agents in Medicinal Chemistry Imaging Findings of Primary Non-functioning Hepatic Paraganglioma: A Case Report
Current Medical Imaging Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey
Current Pharmaceutical Biotechnology Recent Advances in the Mitsunobu Reaction: Modifications and Applications to Biologically Active Molecules
Current Organic Chemistry Human Amniotic Fluid Stem Cells as an Attractive Tool for Clinical Applications
Current Stem Cell Research & Therapy Chimeric Herpes Simplex Virus/Adeno-Associated Virus Amplicon Vectors
Current Gene Therapy Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Current Neuropharmacology Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors from the Natural Origin: A Recent Perspective
Anti-Cancer Agents in Medicinal Chemistry Current Concepts for the Combined Treatment Modality of Ionizing Radiation with Anticancer Agents
Current Pharmaceutical Design Hedgehog Target Genes: Mechanisms of Carcinogenesis Induced by Aberrant Hedgehog Signaling Activation
Current Molecular Medicine Role of Translocator Protein in Renal Ischemia Reperfusion, Renal Preservation and Acute Kidney Injury
Current Molecular Medicine Pyruvate Dehydrogenase Kinases in the Nervous System: Their Principal Functions in Neuronal-glial Metabolic Interaction and Neuro-metabolic Disorders
Current Neuropharmacology Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic
Current Pharmaceutical Design Unsupervised End-to-End Brain Tumor Magnetic Resonance Image Registration Using RBCNN: Rigid Transformation, B-Spline Transformation and Convolutional Neural Network
Current Medical Imaging Neurosarcoidosis
Current Neuropharmacology A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Current Pharmaceutical Biotechnology Clinical Development of Experimental Virus-Mediated Gene Therapy for Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry